Skip to main content

and
  1. Article

    Open Access

    The trajectory of a range of commonly captured symptoms with standard care in people with kidney failure receiving haemodialysis: consideration for clinical trial design

    Despite the recognized high symptom prevalence in haemodialysis population, how these symptoms change over time and its implications for clinical practice and research is poorly understood.

    Pann Ei Hnynn Si, Mónica Hernández-Alava, Louese Dunn, Martin Wilkie in BMC Nephrology (2023)

  2. Article

    Open Access

    Enabling QALY estimation in mental health trials and care settings: map** from the PHQ-9 and GAD-7 to the ReQoL-UI or EQ-5D-5L using mixture models

    Patient-reported outcome measures (PROMs) are commonly collected in trials and some care settings, but preference-based PROMs required for economic evaluation are often missing. For these situations, map** m...

    Matthew Franklin, Monica Hernández Alava in Quality of Life Research (2023)

  3. Article

    Open Access

    Catalogues of EQ-5D-3L Health-Related Quality of Life Scores for 199 Chronic Conditions and Health Risks for Use in the UK and the USA

    Health-related quality of life (HRQoL) measures are essential in economic evaluation, but sometimes primary sources are unavailable, and information from secondary sources is required. Existing HRQoL UK/US cat...

    Michael Falk Hvidberg, Mónica Hernández Alava in PharmacoEconomics (2023)

  4. Article

    Open Access

    Cost Effectiveness of Difelikefalin Compared to Standard Care for Treating Chronic Kidney Disease Associated Pruritus (CKD-aP) in People with Kidney Failure Receiving Haemodialysis

    Chronic kidney disease-associated pruritus (CKD-aP) is associated with an increased risk of depression, poor sleep and reduced health-related quality of life. Two phase III studies (KALM-1 and KALM-2) of difel...

    Praveen Thokala, Pann Ei Hnynn Si, Monica Hernandez Alava in PharmacoEconomics (2023)

  5. Article

    Open Access

    Estimating the Relationship Between EQ-5D-5L and EQ-5D-3L: Results from a UK Population Study

    The aim of this study was to estimate the relationship between EQ-5D-3L and EQ-5D-5L, in both directions, using a single model.

    Mónica Hernández Alava, Steve Pudney, Allan Wailoo in PharmacoEconomics (2023)

  6. Article

    Open Access

    Correction to: Map** the EORTC QLQ-C30 to EQ-5D-3L in patients with breast cancer

    Laura A. Gray, Monica Hernandez Alava, Allan J. Wailoo in BMC Cancer (2022)

  7. Article

    Open Access

    Map** the EORTC QLQ-C30 to EQ-5D-3L in patients with breast cancer

    The types of outcomes measured collected in clinical studies and those required for cost-effectiveness analysis often differ. Decision makers routinely use quality adjusted life years (QALYs) to compare the be...

    Laura A. Gray, Monica Hernandez Alava, Allan J. Wailoo in BMC Cancer (2021)

  8. Article

    Open Access

    Map** EQ-5D-3L from the Knee Injury and Osteoarthritis Outcome Score (KOOS)

    To develop a map** model to estimate EQ-5D-3L from the Knee Injury and Osteoarthritis Outcome Score (KOOS).

    Ali Kiadaliri, Monica Hernández Alava, Ewa M. Roos in Quality of Life Research (2020)

  9. No Access

    Article

    The Impact of Moving from EQ-5D-3L to -5L in NICE Technology Appraisals

    The EuroQol-5 Dimension (EQ-5D) instrument is the National Institute for Health and Care Excellence (NICE)’s preferred measure of health-related quality of life (QoL) in adults. The three-level (3L) value set ...

    Becky Pennington, Monica Hernandez-Alava, Stephen Pudney, Allan Wailoo in PharmacoEconomics (2019)

  10. Article

    Open Access

    Family lifestyle dynamics and childhood obesity: evidence from the millennium cohort study

    The prevalence of childhood obesity has been increasing but the causes are not fully understood. Recent public health interventions and guidance aiming to reduce childhood obesity have focused on the whole fam...

    Laura A. Gray, Monica Hernandez Alava, Michael P. Kelly in BMC Public Health (2018)

  11. No Access

    Article

    Predicting Productivity Losses from Health-Related Quality of Life Using Patient Data

    This paper estimates productivity loss using the health of the patient in order to allow indirect estimation of these costs for inclusion in economic evaluation.

    Clara Mukuria, Donna Rowen in Applied Health Economics and Health Policy (2017)

  12. Article

    Open Access

    Children’s Development and Parental Input: Evidence From the UK Millennium Cohort Study

    In this study, we use the UK Millennium Cohort Study to estimate a dynamic factor model of child development. Our model follows the children from birth until 7 years of age and allows for both cognitive and no...

    Mónica Hernández-Alava, Gurleen Popli in Demography (2017)

  13. No Access

    Article

    Estimating informal care inputs associated with EQ-5D for use in economic evaluation

    This paper estimates informal care need using the health of the patient. The results can be used to predict changes in informal care associated with changes in the health of the patient measured using EQ-5D.

    Donna Rowen, Simon Dixon in The European Journal of Health Economics (2016)

  14. Article

    Open Access

    Modelling the relationship between the WOMAC osteoarthritis index and EQ-5D

    Economic evaluation typically is conducted using health state utilities to estimate treatment benefits. However, such outcomes are often missing from studies of clinical effectiveness. This study aims to bridg...

    Allan Wailoo, Monica Hernandez Alava in Health and Quality of Life Outcomes (2014)

  15. No Access

    Article

    Good Practice Guidelines for the use of Statistical Regression Models in Economic Evaluations

    Decision-analytic models (DAMs) used to evaluate the cost effectiveness of interventions are pivotal sources of evidence used in economic evaluations. Parameter estimates used in the DAMs are often based on th...

    Ben Kearns, Roberta Ara, Allan Wailoo, Andrea Manca in PharmacoEconomics (2013)